Fundamental Analysis of PROTAGENIC THERAPEUTICS INC(NASDAQ:PTIX) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to PTIX. PTIX was compared to 568 industry peers in the Biotechnology industry. While PTIX seems to be doing ok healthwise, there are quite some concerns on its profitability. PTIX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

PTIX had negative earnings in the past year.

In the past year PTIX has reported a negative cash flow from operations.

PTIX had negative earnings in each of the past 5 years.

PTIX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -374.44%, PTIX is doing worse than 96.28% of the companies in the same industry.

The Return On Equity of PTIX (-785.49%) is worse than 82.48% of its industry peers.

		Industry Rank	Sector Rank
ROA	-374.44%
ROE	-785.49%
ROIC	N/A

ROA(3y)-67.04%

ROA(5y)-139.9%

ROE(3y)-77.87%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PTIX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PTIX has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, PTIX has more shares outstanding

PTIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

PTIX has an Altman-Z score of -40.18. This is a bad value and indicates that PTIX is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -40.18, PTIX is doing worse than 93.10% of the companies in the same industry.

PTIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-40.18

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

PTIX has a Current Ratio of 1.80. This is a normal value and indicates that PTIX is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.80, PTIX is doing worse than 78.41% of the companies in the same industry.

PTIX has a Quick Ratio of 1.80. This is a normal value and indicates that PTIX is financially healthy and should not expect problems in meeting its short term obligations.

PTIX has a Quick ratio of 1.80. This is in the lower half of the industry: PTIX underperforms 76.81% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.8
Quick Ratio	1.8

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for PTIX have decreased strongly by -39.55% in the last year.

EPS 1Y (TTM)-39.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%56.13%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTIX. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PTIX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROTAGENIC THERAPEUTICS INC

NASDAQ:PTIX (12/20/2024, 8:00:01 PM)

After market: 0.6799 +0.08 (+13.3%)

0.6001

-0.06 (-8.52%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2024-11-12/amc

Earnings (Next)N/A N/A

Inst Owners8.95%

Inst Owner Change3.32%

Ins Owners20.65%

Ins Owner Change0%

Market Cap4.07M

Analysts82.86

Price TargetN/A

Short Float %1.69%

Short Ratio0.46

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	5.67
P/tB	5.67
EV/EBITDA	N/A

EPS(TTM)-1.27

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.68

FCFYN/A

OCF(TTM)-0.67

OCFYN/A

SpS0

BVpS0.11

TBVpS0.11

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-374.44%
ROE	-785.49%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-67.04%

ROA(5y)-139.9%

ROE(3y)-77.87%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.8
Quick Ratio	1.8
Altman-Z	-40.18

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-39.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%56.13%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-32.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-108.79%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-104.56%

OCF growth 3YN/A

OCF growth 5YN/A

PROTAGENIC THERAPEUTICS INC (PTIX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens